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Abstract
Aim: The aim of this study was to determine the seroprevalence of Hepatitis E virus (HEV) among blood donors in southwest
Switzerland.
Background: HEV is recognized as a food-borne disease in industrialized countries, transmitted mainly through pork meat.
Cases of transmission through blood transfusion have also been reported. Recent studies have revealed seroprevalence
rates of 13.5%, 16.6% and 20.6% among blood donors in England, France and Denmark, respectively.
Methods: We analyzed 550 consecutive blood donor samples collected in the region of Lausanne, canton of Vaud,
Switzerland, for the presence of anti-HEV IgG, using the MP Diagnostics HEV ELISA kit. For each donor, we documented age,
sex and alanine aminotransferase (ALT) value.
Results: The study panel was composed of 332 men (60.4%) and 218 women (39.6%). Overall, anti-HEV IgG was found in 27
of 550 samples (4.9%). The seroprevalence was 5.4% (18/332) in men and 4.1% (9/218) in women. The presence of anti-HEV
IgG was not correlated with age, gender or ALT values. However, we observed a peak in seroprevalence of 5.3% in
individuals aged 51 to 70 years old.
Conclusions: Compared with other European countries, HEV seroprevalence among blood donors in southwest Switzerland
is low. The low seroprevalence may be explained by the sensitivity of commercial tests used and/or the strict regulation of
animal and meat imports. Data regarding HEV prevalence in Swiss livestock are lacking and merit exploration.
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Introduction
Hepatitis E virus (HEV) was discovered in 1983 and cloned in
1991. The virus is transmitted predominantly by way of the enteral
route and may cause waterborne epidemics of hepatitis in
developing countries. Whereas human-to-human transmission
appears to be exceptional, mother-to-child and blood transfusion
transmission have been described [1,2].
HEV isolates are classified into five major genotypes which belong
tothesameserotype. Genotypes differ withrespect to host species and
epidemiological distribution. Genotypes 1 and 2 infect only humans
and are endemic in many parts of Asia, Africa and South America.
Genotypes 3 and 4 infect humans, pigs and other animal species.
Genotype 3 causes sporadic cases of acute hepatitis in North and
South America, Europe and Asia whereas genotype 4 is essentially
restricted to Asia. Genotype 5 infects avian species [2,3].
Imported and autochthonous cases (mainly genotype 3) are
observed in developed countries. For reasons that are incompletely
understood, high HEV seroprevalence rates have been found
among blood donors in southwest France (16.6%), southwest
England (16%), Denmark (20.6%) and the USA (18.3%) (Table 1),
with a large proportion of infections acquired locally [4–8].
Attempts to explain these findings led to the discovery of new
transmission routes, including zoonotic sources. Some genotypes,
namely 3 and 4, are able to infect pigs, wild boars and other
mammals. Viral RNA has been found in pig livers sold commercially
[9]. Pork and other meat products, particularly if undercooked, are
thus considered an important transmission route in developed
countries [1]. Risk factors for HEV infection include professional
exposure to animals (farmers, hunters), age (older populations) and
male gender. Other groups considered at high risk for HEV infection
are hemodialysis patients, injecting drug users and prisoners [10].
HEV infection is often asymptomatic but can induce a self-
limited acute hepatitis, similar to hepatitis A. In pregnant women,
HEV severity is increased with mortality rates up to 20%. HEV
infection can also be severe in individuals with underlying liver
disease in whom mortality rate may reach up to 60% [2,11]. Cases
of chronic HEV infection have been documented in immunosup-
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for malignancies or those infected with HIV [12–14].
There are no recent data regarding HEV seroprevalence in
Switzerland. In 1994, Lavanchy et al reported a seroprevalence of
3.2% among 94 blood donors [15]. In the light of the recent high
HEV seroprevalence reported in various European countries, we
aimed to assess the current HEV seroprevalence rate among blood
donors in Switzerland.
Materials and Methods
Ethics statement
All donors had previously completed the national medical
questionnaire to verify that they fulfilled the criteria for blood
donation and all had provided written consent for the use of blood
samples in medical research after anonymization. The study was
approved by the Ethical Committee of the Canton of Vaud,
Switzerland.
Population and sample collection
Anonymized blood samples were collected consecutively in
November 2009, from 550 blood donors living in the region of
Lausanne, canton of Vaud, in southwest Switzerland. This region
comprises both urban and rural areas, the latter being used for
both arable and livestock-based farming. In order to study a
population close to the general population, blood collections at
university campuses and army centers were excluded.
Anti-HEV serology
Serum anti-HEV IgG was detected by the MP Diagnostics
HEV ELISA kit (MP Biomedicals, formerly Genelabs Diagnostics,
Singapore). This assay uses three recombinant polypeptides
derived from the 39 termini of open reading frame (ORF) 2 (42
amino acids) and ORF3 (33 amino acids) from Burmese and
Mexican prototype sequences (genotypes 1 and 2, respectively).
The tests were performed according to the manufacturer’s
instructions. Initially reactive samples were retested and those
with a repeatedly reactive result were considered positive. The
absorbance/cut-off ratios observed for all samples are depicted in
Figure 1. According to the manufacturer, kit sensitivity and
specificity are 97% and 98%, respectively, in regions of low
endemicity [16].
Data collection
For each blood donation we obtained the results of the routine
screening tests performed by the Blood Transfusion Center,
namely anti-HIV and HIV PCR, HBsAg and HBV PCR, anti-
HCV and HCV PCR, TPHA and alanine aminotransferase
(ALT). Age and gender for each donor were also collected from
the blood bank database.
Statistical analyses
The Lorenz formula was used for sample size calculation,
aiming for a degree of precision of 1.5% and a confidence interval
of 95%. Assuming an anti-HEV prevalence of 3%, we estimated a
minimal sample size requirement of 500 individuals [15].
Data analysis included descriptive statistics of means (with
standard deviation) and medians (with 90% range), depending on
the distribution of the data. Categorical data were assessed in two-
way contingency table analyses using Pearson X2 tests or Fisher’s
exact test when sample size was small. Odds ratios with 95%
confidence intervals were calculated.
All statistical analysis was performed using SAS 9.1 (SAS
Institute Inc., Cary, NC) where P,0.05 was considered significant.
Results
General characteristics of the 550 blood donors examined are
summarized in Table 2. The study panel was composed of 332
men and 218 women. Their age ranged from 27 to 86 years with a
median of 55 years (IQR 46–63 years). 193 donors (35.1%) were
aged 50 years or less, while 357 (64.9%) were older than 50 years.
Table 1. Comparison of HEV seroprevalence in developed countries.
Refe-
rence
Country
of study
Seropre-
valence %
Year of
publication
Subjects
studied (n)
Sex ratio
m/f
Median
Age
Laboratory
test used
[23] Netherlands 1.1 1993 1275 na na Abbott, Diagnostics
Biotechnology
[18] Italy 1.0 1994 948 2.2 36.9 Abbott
[15] Switzerland 3.2 1994 94 na na Abbott, confirmation by
Western-blot assay
[24] Spain 2.8 1998 863 na na Abbott, confirmation by
Western-blot assay
[25] NW Greece 0.2 1998 2636 5.38 42 Abbott
[25] W Greece 0.5 1998 280 1.9 41 Abbott
[8] USA 18.3 2002 400 na na In-house
[17] N France 3.2 2007 1998 1.5 a Genelabs Diagnostics
[4] Denmark 20.6 2008 461 na na In-house
[5] England 16 2008 500 na na Wantai
[7] SW France 16.6 2008 529 1.74 41 Genelabs Diagnostics
[26] SW England 15.8 2008 487 na na Wantai
This Study Switzerland 4.9 2010 550 1.52 55 MP Biomedicals, formerly
Genelabs Diagnostics
Abbreviations: na, data not available.
doi:10.1371/journal.pone.0021150.t001
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being 84 IU/l. Only 4 donors (0.73%) had ALT values over
60 IU/L (normal range, 11–60 IU/L).
Overall, 27/550 blood samples (4.9%) tested positive for IgG
anti-HEV and included 18 samples from men (5.4%) and 9 from
women (4.1%) (P=0.5). HEV seroprevalence varied with age with
a peak at 5.3% (17/303) among donors aged 51 to 70 years old
(P=0.9) (Table 2). Only 6 donors aged 30 years old and younger
were tested, none of whom had a positive result. None of the
samples which tested positive for anti-HEV were associated with
ALT elevation.
None of the blood samples tested positive for anti-HIV, HIV
RNA, HBsAg, HCV RNA or TPHA. One sample (0.18%) tested
positive for anti-HCV but negative for anti-HEV antibodies.
Discussion
We screened 550 blood samples from blood donors in southwest
Switzerland and found that HEV seroprevalence was 4.9%. This
seroprevalence rate is considerably lower than that reported in blood
donors in southwest France, southwest England, Denmark in 2008
and the USA in 2002 [4,5,7,8]. However, our rate was similar to that
reported in Northern France (3.2%) in 2007 and in Italy (0.95%) in
1994 [17,18]. Comparisons between studies are difficult due to
differences in the demographics of the population studied and in the
HEV antibody detection assays used. The various commercially
available tests show important differences in sensitivity. As recently
published by Bendall et al, the MP Diagnostics HEV ELISA kit that
we used may underestimate HEV seroprevalence when compared to
the assay from Wantai (Beijing, China) [19]. In their study, Bendall et
al compared both methods by testing 500 blood samples from blood
donors in Bristol, UK, and found a seroprevalence of 3.6% using the
MP Diagnostics kit and 16.2% usingthe Wantai assay. Sensitivity and
specificity of laboratory tests might further depend upon prevalence,
as well as on the viral genotype present in the study population. Thus,
an HEV ELISA based on genotypes 1 and 2 might not completely
represent genotypes 3 and 4 present in developed countries. In the
absence of standardized commercially available confirmatory assays,
such as Western blots, differences in seroprevalence rates between
different populations must be interpreted with caution.
Our figure of 4.9% is comparable to that observed among blood
donors by Lavanchy et al in Switzerland in 1994 (3.2%) [15]. The
Lavanchy study used an Abbott HEV ELISA kit with a Western
blot confirmation test. As this assay is not the same as the MP
Diagnostics HEV ELISA kit used in our study, we cannot state
with certainty that HEV prevalence in Switzerland has been stable
since 1994. In England, Ijaz conducted a retrospective screening
study comparing seroprevalence rates in blood samples taken in
1991 and 2004 and reported similar seroprevalence rates among
the two groups (13.0% in 1991 and 13.5% in 2004) [20].
Age is known to be correlated with higher HEV seroprevalence
rates. In the study cited above, Ijaz identified as a risk factor the
fact of having lived between 1950 and 1959, rather than being of
increased age per se [20]. Other studies have found older age to be
a risk factor for anti-HEV positivity [4,8]. In our study, older
donors tended to have higher HEV seroprevalence rates, although
differences were not statistically significant (Table 2).
Blood donors are generally healthy, without any recent history
of hepatitis or other illness, or of travel to regions where viral
hepatitis is endemic. Studies based on the general population or
Figure 1. Absorbance/cut-off ratios observed. Samples with initial absorbance/cut-off ratio value.0.90 were retested twice (analyses 2 and 3)
and considered positive if both the 2
nd and 3
rd ratio values were $1.0.
doi:10.1371/journal.pone.0021150.g001
Table 2. Characteristics of the study population.
All
donors
HEV IgG
negative HEV IgG positive
n=550 n=523 (95.1%) n=27 (4.9%)
Sex Male 332 314 (94.6%) 18 (5.4%)
Female 218 209 (95.9%) 9 (4.1%)
ALT #60 IU/L 546 519 (95.1%) 27 (4.9%)
61–100 IU/L 4 4 (100%) 0 (0%)
Age 18–30 6 6 .0 (100%) 0 (0%)
31–50 187 178 (95.2%) 9 (4.8%)
51–70 320 303 (94.7%) 17 (5.3%)
.70 37 36 (97.3%) 1 (2.7%)
Abbreviations: HEV, hepatitis E virus; ALT, alanine aminotransferase.
doi:10.1371/journal.pone.0021150.t002
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donors. In the USA, a seroprevalence rate of 18.3% was observed
among blood donors and 21.0% in the general population [8,21].
In the USA, there are major differences between different parts of
the country, which may be accounted for, at least in part, by
different habits of pork meat consumption [8]. In England, a
seroprevalence rate of 16% was reported among blood donors and
of 13.5% in the general population [5,20]. In a recent Swiss study
of more than 700 HIV-infected patients with unexplained elevated
ALT values, only 2.6% tested positive for anti-HEV IgG using the
MP Diagnostics HEV ELISA Kit, supporting the observation of a
relatively low HEV seroprevalence in Switzerland [13].
As HEV infection in developed countries seems to be a zoonotic
disease transmitted primarily through contaminated meat, we
suspect HEV prevalence to be low in pigs and other mammals in
Switzerland. Over 90% of the pork meat consumed in the country
is produced by regional farmers (Swiss Federal Statistical Office
http://www.bfs.admin.ch//bfs/portal/fr/index.html). However,
the current situation of HEV prevalence among pigs and other
mammals in Switzerland remains unknown. Another possible
reason for the lower seroprevalence we observed is that the
distribution of risk factors such as profession, hobbies, diet, social
status, religion or origin may differ between Swiss blood donors
and those in other countries. We were unable to assess these
factors in detail in our study population. Further studies are
required to clarify the epidemiology and risk factors for HEV
infection in Switzerland and indeed in other countries.
As the presence of HEV RNA was not examined in our study, we
cannot draw conclusions from our results regarding active HEV
prevalence in blood donors and the risk of HEV transmission by
blood transfusion. Further studies are needed to assess the potential
benefit of adding HEV RNA screening of blood products to the
current blood donor selection criteria. Exploring the epidemiology
and risk factors for HEV infection may result in implications
regarding the safety of blood transfusions in the future. Screening
based on ALT level is unsatisfactory as ALT elevation, when it
occurs, does so after the onset of symptoms by which time the HEV
RNA peak has usually subsided [22]. We need to wait until HEV
PCR is commercially available as a screening tool before we can
provide more data in this area.
In summary, we have found an HEV seroprevalence of 4.9%
among blood donors in southwest Switzerland, using the MP
Diagnostics HEV ELISA kit. Our low seroprevalence may be
related to the commercial test we used or to the prevalence of
HEV among Swiss livestock. As both the choice of diagnostic test
and HEV epidemiology may have implications for public health in
general, and blood product screening in particular, these topics
merit further study.
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